IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Income Statement
NASDAQ:IPA - Nasdaq - CA45257F2008 - Common Stock - Currency: USD
| TTM (2025-1-31) | 2024 (2024-4-30) | 2023 (2023-4-30) | 2022 (2022-4-30) | 2021 (2021-4-30) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.00M | 24.52M | 20.66M | 19.36M | 17.91M | |||
| Cost Of Goods | 11.80M | 12.46M | 9.10M | 8.38M | 6.37M | |||
| Gross Profit | 12.20M | 12.05M | 11.56M | 10.98M | 11.54M | |||
| Operating Expenses | 26.65M | 26.15M | 40.11M | 27.23M | 18.46M | |||
| Research and Development | 4.78M | 4.04M | 12.28M | 6.69M | 1.97M | |||
| Selling, General, and Administrative Expenses | 19.32M | 19.14M | 23.42M | 17.97M | 13.75M | |||
| Operating Income | -14.45M | -14.09M | -28.55M | -16.24M | -6.92M | |||
| Interest Income/Expense | -711.00K | 109.00K | 494.00K | 487.00K | -1.59M | |||
| Other Income/Expense | 186.00K | 331.00K | 332.00K | N/A | N/A | |||
| Non Recurring Items | N/A | -15.05M | -27.00K | -92.00K | 2.52M | |||
| Income Before Taxes | -51.19M | -28.70M | -27.75M | -15.85M | -6.00M | |||
| Income Tax | -5.07M | -1.53M | -1.19M | 861.00K | 1.34M | |||
| Net Income | -46.12M | -27.18M | -26.56M | -16.71M | -7.34M | |||
| EBITDA | -8.67M | -8.36M | -21.87M | -12.47M | -3.21M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.57 | -1.06 | -1.07 | -0.85 | -0.45 | |||
| Non GAAP EPS | -0.36 | -0.46 | N/A | N/A | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 50.82% | 49.16% | 55.95% | 56.72% | 64.41% | |||
| Profit Margin | -192.17% | -110.85% | -128.53% | -86.29% | -40.98% | |||
| Operating Profit Margin | -60.22% | -57.48% | -138.16% | -83.88% | -38.63% | |||
All data in CAD